Development and validation of a GC-MS method for the detection and quantification of clotiapine in blood and urine specimens and application to a postmortem case by Mannocchi, Giulio et al.
Research Article
Development and Validation of a GC-MS Method for
the Detection and Quantification of Clotiapine in Blood and
Urine Specimens and Application to a Postmortem Case
Giulio Mannocchi, Flaminia Pantano, Roberta Tittarelli, Miriam Catanese,
Federica Umani Ronchi, and Francesco Paolo Busardò
Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome,
Viale Regina Elena 336, 00161 Rome, Italy
Correspondence should be addressed to Francesco Paolo Busardo`; fra.busardo@libero.it
Received 22 May 2015; Accepted 21 June 2015
Academic Editor: Haopeng Wang
Copyright © 2015 Giulio Mannocchi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Introduction. Clotiapine is an atypical antipsychotic of the dibenzothiazepine class introduced in a few European countries since
1970, efficient in treatment-resistant schizophrenic patients.There is little published data on the therapeutic and toxic concentrations
of this drug. Aims. The aim of the present study is the development and validation of a method that allows the detection
and quantification of clotiapine in blood and urine specimens by gas chromatography-mass spectrometry (GC-MS). Methods.
Validation was performed working on spiked postmortem blood and urine samples. Samples were extracted with liquid-liquid
extraction (LLE) technique at pH 8.5with n-hexane/dichloromethane (85/15 v/v) and analysis was followed byGC-MS.Methadone-
d9 was used as internal standard.Results.The limit of detection (LOD)was 1.2 and 1.3 ng/mL for urine and blood, respectively, while
the lower limit of quantification (LLOQ)was 3.9 and 4.3 ng/mL, respectively. Linearity, precision, selectivity, accuracy, and recovery
were also determined.Themethod was applied to a postmortem case.The blood and urine clotiapine concentrations were 1.32 and
0.49 𝜇g/mL, respectively. Conclusions. A reliable GC-MS method for the detection and quantification of clotiapine in blood and
urine samples has been developed and fully validated and then applied to a postmortem case.
1. Introduction
Clotiapine has been described as both typical and atypical
antipsychotic in literature. It belongs to the dibenzoth-
iazepine chemical class andwas introduced in a fewEuropean
countries since 1970. It is characterized by high incidence
of extrapyramidal side effects, but some authors [1] underlie
its efficacy in treating resistant schizophrenic patients. Its
chemical structure is similar to that of clozapine; structural
similarities are shown in Figure 1.
The mechanism of action of this neuroleptic is due to
downregulation of 5HT2-receptors [2]. Clotiapine shows
also great affinity for 5HT-3,6 receptors. It seems also that
it acts on dopamine receptors [3] and as an antagonist
to histamine, norepinephrine, serotonin, and dopamine in
animal models [4]. It has a rapid onset of action and it
is characterized by marked sedative effects; therefore it is
used to manage acute and chronic schizophrenia, agitation,
bipolar, panic, and sleep disorders [5]. Moreover, it is also
used for the treatment of drug withdrawal symptoms [6],
as suggested by animal studies regarding heroin addiction.
The effects noticed following clotiapine administration were
antidopaminergic, antimuscarinic, and antiadrenergic that
could counteract withdrawal symptoms [7]. This drug is able
to produce anticholinergic adverse reactions in the 25% of
cases as reported by Cicero et al. [8]. In literature the possi-
bility of an increased risk of ventricular arrhythmias, sudden
cardiac death, and drug induced long QT interval is reported
[9, 10]. Moreover, clotiapine has been linked with fatalities in
association with other substances such as clomipramine, [11]
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Figure 1: Chemical structures of clozapine and clotiapine.
alcohol, [12] citalopram, and mirtazapine [13]. Overdose in a
female infant, accompanied by central nervous system (CNS)
depression and managed by supportive treatment without
sequelae, has also been described [14].
Toxicological investigation in the determination of the
cause of death plays a crucial role. In cases of deaths that
are not directly attributed to intoxication itself but related
to pharmacological mechanisms that could contribute to
the development of complex multifactorial syndromes, the
identification of involved drugs is important to assist in the
determination of the cause of death. In this paper, a method
for detection and quantification of clotiapine in blood and
urine samples was developed and fully validated according
to the guidelines of Peters et al. [15]. The method was then
applied to a postmortem case.
2. Case Report
A 45-year-old man (185 cm of body height and 95 kg of body
weight) died in bed in his private flat. Relatives could provide
only limited information about the circumstances of death,
but positive anamnesis about mental illness (schizophrenia)
was reported. A complete autopsy and a full toxicological
analysis were performed.
2.1. Autopsy Results. The external examination revealed only
a remarkable abdominal swelling. The internal examination
showed a moderate pulmonary oedema and the presence
of massive urinary retention: the bladder contained 3.7 L of
urine (Figure 2). The kidneys (weight 270 gr, the right, and
260 gr, the left) were markedly congested.
The pathological evidences in combination with the
referred schizophrenia suggested that a pharmacological
mechanism could have contributed to the massive urinary
retention.
3. Experimental
3.1. Chemicals, Reagents, and Samples. Peripheral blood
(15mL), urine (40mL), and gastric contents (40mL) were
collected during autopsy and stored at −20∘C. The internal
standard selected for quantitative determination of cloti-
apine in biological samples was methadone-d9, purchased
from Cerilliant (Round Rock, TX). Reference standards
Figure 2: Internal examination: overdistended bladder containing
3.7 L of urine.
for clotiapine were purchased from ALSACHIM (Illkirch-
Graffenstaden, France). Ethyl acetate, n-hexane, and dichlo-
romethane were acquired from Carlo Erba (Milan, Italy).
Ultrapure distilled and deionized water was homemade
(Millipore-Helix 70) and filtered prior to use.
3.2. Preparation of Standards. Blank urine and blood sam-
ples, collected from autopsies performed in our depart-
ment, were used to prepare the standard calibration curves,
obtained by fortification with certified standard of clotiapine
in range of concentration from 10 to 2000 ng/mL. 500 ng
of methadone-d9 was added, in each sample, as internal
standard. The samples used to determine the accuracy,
precision, and recovery of the method were prepared as
described above.
3.3. Extraction Procedure. Fortified blank urine and blood
were extracted according to the following procedure: to
1mL of each sample, 1mL of deionized water and 500 ng
of methadone-d9 were added. Samples were extracted at
pH 8.5 (adding 50mg of solid HCO3
−
/CO3
−− buffer)
with 4mL of extraction solution (n-hexane/dichloromethane
(85/15 v/v)) [16] after 15 minutes of steering. After centrifu-
gation (4000 rpm, 3min) the organic layer was evaporated to
dryness under a gentle stream of nitrogen. The residue was
reconstituted in 50𝜇L of ethyl acetate. Gastric content sample
was extracted according to the above mentioned procedure.
3.4. Instrumentation and Conditions. Analysis was carried
out on a gas chromatography instrument Agilent HP 7028A
GC coupled with an AgilentMSD 5975.The capillary column
used was an HP-5MS (17m × 0.25mm I.D. coated with
a 0.25 𝜇m film). The GC conditions were as follows: the
column temperature was programmed from 125∘C to 290∘C
with an increase of 10∘C/min; the injection port and the
transfer line temperature were 270∘C; helium was used as
carrier gas at flow rate of 1mL/min; split ratio was 15 : 1. The
mass analyzer operated by electron impact (70 eV) in selected
ion monitoring (SIM). Quantitative analysis was carried out
recording ions 𝑚/𝑧 209-244-343 for clotiapine and 𝑚/𝑧 78-
165-303 formethadone-d9.The underlined ions were used for
quantitative analysis.
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Table 1: Method validation parameters and data.
Selectivity Linearity (𝑅2) Accuracy (bias%) Precision (RSD%) LOD LLOQ Recovery (%)
Low High Low High Low High
Urine No interference signals 0.9997 18 −0.6 14 3.2 1.2 ng/mL 3.9 ng/mL 103 99
Blood No interference signals 0.9996 −18 −0.5 19 3.0 1.3 ng/mL 4.3 ng/mL 93 95
3.5. Method Validation. The method was validated on urine
and blood specimens, according to the procedure of Peters
et al. [15] “for single case analysis or for analysis of rare
analytes”; in addition, an extra parameter, recovery, was
determined as well.
Selectivitywas evaluated by analysis of six sources of blank
matrices (blood and urine samples collected from autopsies)
processed with 1 zero sample (blank matrix with internal
standard), verifying the absence of signal interferences. The
Calibration Model was selected by analyzing 6 concentration
levels, from 10 ng/mL to 2000 ng/mL, and each level was eval-
uated in triplicate according to a linearmodel.Accuracy (bias)
and precision were estimated from the analysis of quality
control (QC) samples at low (close to lower limit of quan-
tification (LLOQ)) and high concentration (2000 ng/mL), in
five replicates for each level. The acceptance criterion for bias
was within ±15% of nominal value (±20% close to LLOQ),
for precision was within ±15% relative standard deviation
(RSD) (20% close to LLOQ). The LOD (Limit of Detection)
was determined by analysis of spiked samples with decreasing
level of concentration of the analyte. For LOD a value of
signal-to-noise ratio equal to or greater than three (𝑆/𝑁 ≥
3) was chosen. The LLOQ was determined by analysis of
fortified samples with decreasing level of concentration of the
analyte. For LLOQ a value of signal-to-noise ratio equal to
or greater than ten (𝑆/𝑁 ≥ 10) was chosen. Recovery was
calculated by analyzing extracted spiked samples at high and
low concentration in relationship with the curve calibration,
compared with the control samples.
3.6. Determination of Creatinine Concentrations and Creati-
nine-Normalization. The clotiapine concentrations in urine
sampleswere creatinine-normalized [17].The creatinine (CR)
concentration was determined by using an ILab 650 analyzer.
Clotiapine concentrations in urine were CR-normalized
based on a previously published method [17] using the
following equation: concentration CR-normalized = cloti-
apine concentration ⋅ (CR reference)/(CR sample). The CR
reference was 100mg/dL [17].
4. Results
4.1. Validation Results. Themethod was validated by investi-
gating the following parameters: linearity, selectivity, identifi-
cation of LOD and LLOQ, precision, accuracy, and recovery.
The results are shown in Table 1.
The calibration plots showed good linearity, with a deter-
mination coefficient of 0.9996 and 0.9997 in blood and urine,
respectively.
4.2. Toxicological Findings. Toxicological screening, per-
formed with immunochemical technique, revealed the
absence of the most common abuse substances. Alcohol
intake was excluded by performing HS-GC-FID analysis.
A GC-MS screening analysis to evaluate the presence of
drugs that could contribute to urinary retention (according
to the anamnestic data) was carried out in blood and urine.
Clotiapine was found in both matrices.
Afterwards, toxicological analysis, using the validated
method described here, retrieved the following concen-
trations: 1.32, 0.49, and 1.85 𝜇g/mL in peripheral blood,
urine, and gastric contents, respectively. No other drugs or
alcohol was detected in biological samples. Full scan mode
chromatograms and mass spectra as well as SIM mode
chromatograms, indicating clotiapine and methadone-d9,
obtained from the analysis of the blood sample, are given
in Figures 3 and 4, respectively. In Figure 3, the peaks of
extracted ions that were used for qualitative and quantitative
analysis of clotiapine (𝑚/𝑧 209-244-343) are presented. The
retention time of clotiapine as shown in the same figure is
8.755 minutes. In Figure 4, SIM mode chromatograms of
analytes of interest (𝑚/𝑧: 303 for methadone-d9 and 𝑚/𝑧:
343 for clotiapine) are given. The retention times recorded
for methadone-d9 and clotiapine are 6.461 and 8.762, respec-
tively.
5. Discussion and Conclusions
A GC-MS method for the detection and quantification of
clotiapine in blood and urine samples has been developed,
validated, and then successfully applied to real samples. The
application of the method to a fatal case involving a 45-year-
old schizophrenic subject allows us to identify clotiapine at
very high concentrations in blood, urine, and gastric content.
The presence of clotiapine in gastric contents suggests an oral
intake. Because of the remarkable sedative characteristics of
this substance, the deceased could not probably be in a state
to be aware and face the symptoms. Particular caution is
recommended when treating patients with urinary retention
(especially due to prostatic hypertrophy). Moreover, it is
not advisable to coadminister anticholinergic agents and
clotiapine, since the latest could lead to harmful effects
including vision disorders, constipation, urinary retention,
possible increase in intraocular pressure, andmouth dryness.
Lethal dose 50 (LD 50) after oral intake in the mouse,
rat, and Guinea pig is 272, 480, and 154mg/kg, respec-
tively. However, therapeutic, toxic, and fatal doses in human
are still non-well-established [18–21]. The plasma clotiapine
concentrations found in twelve clotiapine-treated patients
ranged from 0.006 to 0.155mg/L (mean 0.046mg/L) while
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Figure 3: Full scan mode chromatogram and mass spectra obtained from blood sample analysis.
the concentrations reported in seven autopsy cases ranged
from 0.022 to 0.341mg/L (mean 0.123mg/L) [16]. However,
in the latest study clotiapine was only a contributing factor
in the cause of death of multidrug intoxications; none of the
deaths was attributed to clotiapine poisoning.
In this case the cause of death taking into considera-
tion the autopsy and toxicological findings was attributed
to postrenal acute kidney injury due to a severe urinary
retention (3.7 L of urine in the bladder).
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Figure 4: SIM mode chromatogram showing methadone-d9 (𝑚/𝑧: 303) and clotiapine (𝑚/𝑧: 343) in blood sample.
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